# Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences Canonical URL: https://biopharmsignal.com/news/OCUL/ocular-therapeutix-to-participate-in-july-scientific-and-investor-conferences-339a542b Ticker: OCUL Company: Ocular Therapeutix Source: Ocular Therapeutix Published: 2026-07-01 11:00 EST ## Summary Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to... ## Article Body Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in July 2026. Upcoming Scientific Conferences : 9 th Annual OIS Retina Innovation Summit (OIS Retina 2026): July 14, 2026 Montréal, Quebec Presentation: Ocular Therapeutix: Retina Experience Redefined Presentation Date/Time: Tuesday, July 14, 2026, 11:37 – 11:44 AM EDT Presenter: Peter K. Kaiser, MD, Chief Development Officer Panel Title: The Impact of Recent FDA Guidance on Drug Development Panel Date/Time: Tuesday, July 14, 2026, 4:40 – 5:20 PM ET Panel Moderator: Pravin U. Dugel, MD, Executive Chairman, President and CEO The American Society of Retina Specialists (ASRS) 44 th Annual Meeting : July 15 - 18, 2026 Montréal, Quebec Presentation: Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular Age-Related Macular Degeneration: Efficacy and Safety Results from the Phase 3 SOL-1 Trial Results Session: Beyond Anti-VEGF: Emerging Durable Therapies in Neovascular AMD Presentation Date/Time: Thursday, July 16, 2026, 8:15 – 8:45 AM EDT Presenter: Dilsher S. Dhoot, MD Presentation: Real-World Anti-VEGF Treatment Utilization and Vision Outcomes in Neovascular Age-Related Macular Degeneration: Analysis of the Vestrum Database Session: Real-world nAMD: Utilization, Outcomes, and Long-Term Anti-VEGF Data Presentation Date/Time: Thursday, July 16, 2026, 8:50 – 8:53 AM EDT Presenter: Andrew A. Moshfeghi, MD, MBA, FASRS On-Demand Paper Title: Anti-VEGF Treatment Patterns and Long-Term Vision Outcomes in Patients with nAMD in the IRIS Registry Session Date/Time: On-demand papers will be continually available for viewing throughout the meeting Presenter: Priya Vakharia, MD Symposium Title: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control Session: Satellite Symposia Symposium Date/Time: Thursday, July 16, 2026, 6:00 – 7:30 PM EDT Faculty: Arshad M. Khanani, MD; Dilsher S. Dhoot, MD; Mark R. Barakat, MD; Peter K. Kaiser, MD, Chief Development Officer; and Jeffrey S. Heier, MD, Chief Scientific Officer Exact medical conference presentation times may be subject to change. Upcoming Investor Conference : HC Wainwright 6 th Annual Ophthalmology Virtual Conference : Date: Wednesday, July 22, 2026 Fireside Chat: 4:30 – 5:00 PM EDT Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO Location: Virtual A live webcast of the fireside chat can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days following the presentation. About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA ® , an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program. Follow the Company on its website, LinkedIn, or X. DEXTENZA ® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc. Investors & Media Ocular Therapeutix, Inc. Bill Slattery Vice President, Investor Relations bslattery@ocutx.com ## Recent Company News - 2026-07-09 20:05 EST — [Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-b366a42e) — Source: Ocular Therapeutix - 2026-07-01 11:00 EST — [Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences](https://biopharmsignal.com/news/OCUL/ocular-therapeutix-to-participate-in-july-scientific-and-investor-conferences-339a542b) — Source: Ocular Therapeutix - 2026-06-22 20:05 EST — [Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-101ec89c) — Source: Ocular Therapeutix - 2026-06-17 12:45 EST — [Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026](https://biopharmsignal.com/news/OCUL/ocular-therapeutix-investor-day-to-highlight-u-s-fda-alignment-on-axpaxli-nda-wi-72a30a89) — Source: Ocular Therapeutix - 2026-06-05 11:00 EST — [Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-20d4bd38) — Source: Ocular Therapeutix ## Related News - 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a) - 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a) - 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2) - 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11) - 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)